



YOU ARE CORDIALLY INVITED TO ATTEND

Beyond Monoamines: Glutamate as an Emerging Treatment Target in Major Depressive Disorder

Topics:

- The history and usage of monoamine-based treatments in major depressive disorder (MDD)
- The normal functioning of the neurotransmitter glutamate in the brain
- The proposed role of glutamate dysfunction in psychiatric disorders, including MDD
- Glutamate modulation as a potential target for MDD

Presented By:

Samantha Fox, FNP-BC
Medication Management Provider
Camelot Care Centers

Date:

Tuesday, September 9, 2025

Time:

6:00 PM Central Time
Meeting Duration: 60 minutes

Meeting Information:

Fleming's Prime Steakhouse
103 Summit Boulevard
Birmingham, AL 35243

Faculty are paid speakers presenting on behalf of Axsome Therapeutics, Inc.

**To reserve your spot, please contact Dana Murdock
at dmurdock@axsome.com or (205) 718-0120**

Please note that there are no certified continuing medical education credits approved for this program.

Axsome Therapeutics, Inc. is committed to the principles of the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals. As part of our commitment to that Code, we cannot pay for any costs incurred for travel or food of spouses or guests of any program participants, and any such spouses or guests may not attend any portion of a program's meeting or event. We appreciate your understanding in this regard.

Prescribers in Minnesota are limited to \$50 per year for meals, Vermont prescribers can't receive meals, and in New Jersey, Limits are \$17 for breakfast and lunch and \$35 for dinner. Meal reporting depends on state and federal laws.



AXSOME and its logos are trademarks or registered trademarks of Axsome Therapeutics, Inc. or its affiliates.
© 2025 Axsome Therapeutics, Inc. All rights reserved. One World Trade Center, 22nd Floor, New York, NY 10007.
PP-DEP-US-2400003 03/2025